Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical application of niacin-induced skin flush response in adolescents with psychiatric disorders and its correlation with clinical blood test indicators.

BMC psychiatry·2026
Same author

Investigation of the molecular mechanism in regulating freeze-thaw deterioration of starch pearls by dextran with different molecular weights.

Food chemistry·2026
Same author

Engineered Nonheme Iron Enzymes Enable Asymmetric Hydrogenation of Alkenes.

Journal of the American Chemical Society·2026
Same author

A comprehensive survey on diagnosis and assessment of Parkinson's disease via plantar pressure analysis.

NPJ Parkinson's disease·2026
Same author

Determination of patient prognosis based on unruptured basilar artery aneurysm morphology using a novel dynamic prediction model.

Frontiers in neurology·2026
Same author

Longitudinal Diffusion MRI Characterizes Persistent Perivascular Diffusivity Asymmetry and White Matter Abnormalities After Cranioplasty for Decompressive Craniectomy.

Diagnostics (Basel, Switzerland)·2026
Same journal

Screening of Medicinal and Edible Homology Substances for Diabetic Kidney Disease Based on GraphBAN.

Current medicinal chemistry·2026
Same journal

Berberine as an Antimicrobial Agent and Gut Microbiota Modulator: Mechanisms and Therapeutic Potential.

Current medicinal chemistry·2026
Same journal

Research Progress of Grapefruit-derived Extracellular Vesicles in Anti-tumor Treatment.

Current medicinal chemistry·2026
Same journal

Corrigendum to: Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke.

Current medicinal chemistry·2026
Same journal

Ferroptosis and Its Crosstalk with Other Cell Death Modes in Ischemic Stroke.

Current medicinal chemistry·2026
Same journal

Integrative Analysis Reveals BPTF, COL1A1, and COL4A2 as Fibroblast-Related Biomarkers Associated with Immune Infiltration in Ovarian Cancer.

Current medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Rationally designed multitarget anticancer agents.

Zhuo Chen1, Le Han, Minghao Xu

  • 1State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.

Current Medicinal Chemistry
|February 16, 2013
PubMed
Summary
This summary is machine-generated.

Multitarget antitumor agents offer advantages over drug combinations for treating complex cancers. This review focuses on pharmacophore-based designs, highlighting their effectiveness against drug-resistant cancer cells.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Experiment Videos

Last Updated: May 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Complex diseases like cancer often require targeting multiple pathways.
  • Single molecules modulating multiple targets offer pharmacokinetic and pharmacodynamic advantages over drug combinations.
  • Increasing drug resistance in cancer necessitates novel therapeutic strategies.

Purpose of the Study:

  • To provide an overview of multitarget antitumor agents based on pharmacophore design.
  • To highlight the design strategies for these agents, including pharmacophore combination and high-throughput screening.
  • To emphasize the importance of validating these agents against multiple targets in various systems.

Main Methods:

  • Review of reported multitarget antitumor agents.
  • Analysis of agent design strategies focusing on pharmacophores.
  • Examination of validation studies in cell-free systems, cancer cells, and resistant cell lines.

Main Results:

  • Identified privileged pharmacophores like quinazoline, phenylaminopyrimidine, anthracycline, and naphthalimide in multitarget agent design.
  • Demonstrated the effectiveness of these agents in both cell-free and cellular assays.
  • Confirmed the potency of multitarget compounds against drug-resistant cancer cell lines.

Conclusions:

  • Pharmacophore-based design is a viable strategy for developing multitarget antitumor agents.
  • In-depth validation across multiple targets and models is crucial for assessing efficacy.
  • Multitarget agents show significant promise in overcoming cancer drug resistance.